Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Más filtros










Intervalo de año de publicación
1.
Clin Pharmacol Drug Dev ; 13(3): 288-296, 2024 03.
Artículo en Inglés | MEDLINE | ID: mdl-38171911

RESUMEN

Smallpox was eradicated in 1980 but remains a biothreat due to the potential release of variola virus into the general population. Brincidofovir, the second medicine approved by the US Food and Drug Administration to treat smallpox, is metabolized by oxidative and hydrolytic pathways. The oxidative pathway is initiated by cytochrome P450 4F2 (CYP4F2), an enzyme lacking clinical probes for drug interaction studies. The aim of this work was to assess the impact of reduced activity CYP4F2 variants (rs2108622, C/T and T/T) on brincidofovir pharmacokinetics as a surrogate for drug inhibition. Genotyping was performed on blood from healthy participants receiving oral (n = 261) and intravenous (IV, n = 49) brincidofovir across 6 phase 1 trials. Plasma concentrations were measured by validated liquid chromatography tandem mass spectrometry methods. After oral administration, subjects with the lowest activity CYP4F2 genotype (T/T) had up to 36% higher AUCinf and 29% higher Cmax while subjects with the moderate activity CYP4F2 genotype (C/T) had similar Cmax and AUCinf compared to those with the wild-type genotype. Little to no increase in brincidofovir exposure parameters was observed following IV administration. Based on the lack of significant increases in brincidofovir plasma concentrations in subjects with low activity CYP4F2, a clinically meaningful drug-drug interaction is not expected with CYP4F2 inhibitor and brincidofovir coadministration.


Asunto(s)
Citosina/análogos & derivados , Organofosfonatos , Viruela , Estados Unidos , Humanos , Genotipo , Interacciones Farmacológicas , Sistema Enzimático del Citocromo P-450
2.
3.
Clin Pharmacol Ther ; 113(2): 328-338, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-36281788

RESUMEN

Inclisiran is a novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) therapy designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in the liver for the treatment of hypercholesterolemia. Inclisiran's GalNAc attachment results in a rapid uptake into the liver, and thus a short plasma half-life, but long duration of effects on PCSK9 inhibition and low-density lipoprotein cholesterol (LDL-C) lowering. The effects on PCSK9 inhibition and consequent LDL-C reduction are sustained for more than 6 months following a single subcutaneous (s.c.) dose, despite inclisiran being detectable in the plasma only for up to 48 hours. A kinetic-pharmacodynamic (K-PD) model was developed to characterize inclisiran's dose-related LDL-C lowering effects and to evaluate the impact of intrinsic and extrinsic factors on LDL-C lowering. To accommodate the long duration of action, the K-PD model incorporated an effect compartment which represents the liver. Inclisiran concentration in the liver leads to decreased production of the PCSK9 protein and allow recycling of more LDL-C receptors on the hepatocyte cell surface, which results in a reduction of circulating LDL-C. The analysis of covariates identified PCSK9 and LDL-C baseline levels as important factors for the effects of LDL-C lowering. Observations and modeling and simulation results demonstrated that PCSK9 and LDL-C reductions are achieved rapidly after dosing and sustained when patients are treated with a 300 mg s.c. dose once every 6 months.


Asunto(s)
Anticolesterolemiantes , Hipercolesterolemia , Humanos , Hipercolesterolemia/tratamiento farmacológico , Proproteína Convertasa 9/genética , LDL-Colesterol , ARN Interferente Pequeño/genética
4.
Clin Pharmacol Ther ; 109(4): 867-891, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33555032

RESUMEN

Model-informed drug development (MIDD) has a long and rich history in infectious diseases. This review describes foundational principles of translational anti-infective pharmacology, including choice of appropriate measures of exposure and pharmacodynamic (PD) measures, patient subpopulations, and drug-drug interactions. Examples are presented for state-of-the-art, empiric, mechanistic, interdisciplinary, and real-world evidence MIDD applications in the development of antibacterials (review of minimum inhibitory concentration-based models, mechanism-based pharmacokinetic/PD (PK/PD) models, PK/PD models of resistance, and immune response), antifungals, antivirals, drugs for the treatment of global health infectious diseases, and medical countermeasures. The degree of adoption of MIDD practices across the infectious diseases field is also summarized. The future application of MIDD in infectious diseases will progress along two planes; "depth" and "breadth" of MIDD methods. "MIDD depth" refers to deeper incorporation of the specific pathogen biology and intrinsic and acquired-resistance mechanisms; host factors, such as immunologic response and infection site, to enable deeper interrogation of pharmacological impact on pathogen clearance; clinical outcome and emergence of resistance from a pathogen; and patient and population perspective. In particular, improved early assessment of the emergence of resistance potential will become a greater focus in MIDD, as this is poorly mitigated by current development approaches. "MIDD breadth" refers to greater adoption of model-centered approaches to anti-infective development. Specifically, this means how various MIDD approaches and translational tools can be integrated or connected in a systematic way that supports decision making by key stakeholders (sponsors, regulators, and payers) across the entire development pathway.


Asunto(s)
Antiinfecciosos/farmacología , Desarrollo de Medicamentos/organización & administración , Modelos Biológicos , United States Food and Drug Administration/organización & administración , Antibacterianos/farmacología , Antiinfecciosos/farmacocinética , Antifúngicos/farmacología , Antimaláricos/farmacología , Antituberculosos/farmacología , Antivirales/farmacología , Peso Corporal , Relación Dosis-Respuesta a Droga , Aprobación de Drogas/organización & administración , Descubrimiento de Drogas/organización & administración , Farmacorresistencia Microbiana/efectos de los fármacos , Farmacorresistencia Microbiana/fisiología , Humanos , Inmunidad/fisiología , Ivermectina/uso terapéutico , Pruebas de Función Renal , Pruebas de Función Hepática , Pruebas de Sensibilidad Microbiana , Oncocercosis Ocular/tratamiento farmacológico , Pediatría , Proyectos de Investigación , Estados Unidos , United States Food and Drug Administration/normas
5.
J Med Chem ; 63(20): 11882-11901, 2020 10 22.
Artículo en Inglés | MEDLINE | ID: mdl-32914979

RESUMEN

Herein, we report spiropyrimidinetriones (SPTs) incorporating N-linked azole substituents on a benzisoxazole scaffold with improved Gram-positive antibacterial activity relative to previously described analogues. SPTs have an unusual spirocyclic architecture and represent a new antibacterial class of bacterial DNA gyrase and topoisomerase IV inhibitors. They are not cross-resistant to fluoroquinolones and other DNA gyrase/topoisomerase IV inhibitors used clinically. The activity of the SPTs was assessed for DNA gyrase inhibition, and the antibacterial activity across Gram-positive and Gram-negative pathogens with N-linked 1,2,4-triazoles substituted on the 5-position provides the most worthwhile profile. Directed nucleophilic and electrophilic chemistry was developed to vary this 5-position with carbon, nitrogen, or oxygen substituents and explore structure-activity relationships including those around a target binding model. Compounds with favorable pharmacokinetic parameters were identified, and two compounds demonstrated cidality in a mouse model of Staphylococcus aureus infection.


Asunto(s)
Antibacterianos/farmacología , Girasa de ADN/metabolismo , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Inhibidores de Topoisomerasa II/farmacología , Animales , Antibacterianos/síntesis química , Antibacterianos/química , Azoles/química , Azoles/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Isoxazoles/química , Isoxazoles/farmacología , Ratones , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Pirimidinonas/síntesis química , Pirimidinonas/química , Pirimidinonas/farmacología , Ratas , Ratas Wistar , Compuestos de Espiro/síntesis química , Compuestos de Espiro/química , Compuestos de Espiro/farmacología , Infecciones Estafilocócicas/metabolismo , Staphylococcus aureus/metabolismo , Relación Estructura-Actividad , Inhibidores de Topoisomerasa II/síntesis química , Inhibidores de Topoisomerasa II/química
6.
J Antimicrob Chemother ; 73(5): 1295-1304, 2018 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-29415212

RESUMEN

Objectives: To characterize quantitatively the effect of avibactam in potentiating ceftazidime against MDR Pseudomonas aeruginosa by developing a mathematical model to describe the bacterial response to constant concentration time-kill information and validating it using both constant and time-varying concentration-effect data from in vitro and in vivo infection systems. Methods: The time course of the bacterial population dynamics in the presence of static concentrations of ceftazidime and avibactam was modelled using a two-state pharmacokinetic/pharmacodynamic (PK/PD) model, consisting of active and resting states, to account for bactericidal activities, bacteria-mediated ceftazidime degradation and inhibition of degradation by avibactam. Ceftazidime's effect on the bacterial population was described as an enhancement of the death rate of the active population, with the effect of avibactam being to increase ceftazidime potency. Model validation was performed by comparing simulated time courses of bacterial responses with those from in vitro and in vivo experimental exposures of ceftazidime and avibactam that represented those predicted in an average patient dosed with 2 g/0.5 g ceftazidime/avibactam administered every 8 h as 2 h infusions. Results: The two-state model successfully described the bacterial population dynamics, ceftazidime degradation and its inhibition by avibactam. For external validation, the model correctly predicted the bacterial response of P. aeruginosa isolates evaluated in in vitro hollow-fibre and in vivo neutropenic mouse thigh and lung infection models. Conclusions: The PK/PD model and modelled strains successfully replicated the spread in activity when compared with a large selection of P. aeruginosa strains reported in the literature.


Asunto(s)
Antibacterianos/farmacología , Compuestos de Azabiciclo/farmacología , Ceftazidima/farmacología , Viabilidad Microbiana/efectos de los fármacos , Modelos Teóricos , Pseudomonas aeruginosa/efectos de los fármacos , Inhibidores de beta-Lactamasas/farmacología , Animales , Antibacterianos/farmacocinética , Compuestos de Azabiciclo/farmacocinética , Ceftazidima/farmacocinética , Simulación por Computador , Combinación de Medicamentos , Femenino , Humanos , Cinética , Masculino , Ratones , Infecciones por Pseudomonas/microbiología , Factores de Tiempo , Inhibidores de beta-Lactamasas/farmacocinética
7.
J Antimicrob Chemother ; 72(4): 1109-1117, 2017 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-28077672

RESUMEN

Objectives: This study evaluated the in vitro pharmacodynamics of combinations of ceftazidime and the non-ß-lactam ß-lactamase inhibitor, avibactam, against ceftazidime-, piperacillin/tazobactam- and meropenem-multiresistant Pseudomonas aeruginosa by a quantitative time-kill method. Methods: MICs of ceftazidime plus 0-16 mg/L avibactam were determined against eight isolates of P. aeruginosa . Single-compartment, 24 h time-kill kinetics were investigated for three isolates at 0-16 mg/L avibactam with ceftazidime at 0.25-4-fold the MIC as measured at the respective avibactam concentration. Ceftazidime and avibactam concentrations were measured by LC-MS/MS during the time-kill kinetic studies to evaluate drug degradation. Results: Avibactam alone displayed no antimicrobial activity. MICs of ceftazidime decreased by 8-16-fold in the presence of avibactam at 4 mg/L. The changes in log 10 cfu/mL at both the 10 h and 24 h timepoints (versus 0 h) revealed bacterial killing at ≥1-fold MIC. Significantly higher concentrations of ceftazidime alone, as compared with those of ceftazidime in combination, were required to produce any given kill. Without avibactam, ceftazidime degradation was significant (defined as degradation t 1/2 < 24 h), with as little as 19% ± 18% of the original concentration remaining at 8 h for the most resistant strain. In combination with avibactam, ceftazidime degradation at ≥ 1-fold MIC was negligible. Conclusion: The addition of avibactam protected ceftazidime from degradation in a dose-dependent manner and restored its cidal and static activity at concentrations in combination well below the MIC of ceftazidime alone.


Asunto(s)
Antibacterianos/farmacología , Compuestos de Azabiciclo/farmacología , Ceftazidima/farmacología , Ácido Penicilánico/análogos & derivados , Pseudomonas aeruginosa/efectos de los fármacos , Resistencia betalactámica , Inhibidores de beta-Lactamasas/farmacología , Ceftazidima/metabolismo , Sinergismo Farmacológico , Cinética , Meropenem , Pruebas de Sensibilidad Microbiana/métodos , Ácido Penicilánico/farmacología , Piperacilina/farmacología , Combinación Piperacilina y Tazobactam , Espectrometría de Masas en Tándem/métodos , Tienamicinas/farmacología
8.
J Antimicrob Chemother ; 71(7): 1866-80, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27107096

RESUMEN

OBJECTIVES: The combination of aztreonam and avibactam has been proposed for the treatment of infections caused by metallo-ß-lactamase-producing Gram-negative organisms, given the stability of aztreonam against metallo-ß-lactamases plus the broad coverage of avibactam against AmpC ß-lactamases and ESBLs. This study aimed to evaluate the efficacy of the combination against four clinical isolates with defined but diverse ß-lactamase profiles. METHODS: The MICs of aztreonam were determined without and with avibactam (1, 2, 4, 8 and 16 mg/L). Using the MIC values, the static time-kill kinetic studies were designed to encompass aztreonam concentrations of 0.25, 0.5, 1, 2 and 4 times the MIC at the respective avibactam concentrations from 0 to 8 mg/L. Aztreonam and avibactam concentrations were determined by LC-MS/MS during the course of the time-kill kinetic studies to evaluate whether avibactam protects aztreonam from degradation. RESULTS: Three of the four isolates had aztreonam MICs ≥128 mg/L in monotherapy. Dramatically increasing susceptibility associated with a decrease in aztreonam MIC was observed with increasing avibactam concentration. Against all isolates, the combinations resulted in greater killing with a much lower dose requirement for aztreonam. The resulting changes in base-10 logarithm of cfu/mL at both the 10 h and 24 h references (versus 0 h) were synergistic. In contrast, a significantly higher concentration of aztreonam in the monotherapy was required to produce the same kill as that in the combination therapy, due to rapid aztreonam degradation in two isolates. CONCLUSIONS: The aztreonam/avibactam combination protects aztreonam from hydrolysis and provides synergy in antimicrobial activity against multiple ß-lactamase-expressing strains with a wide MIC range.


Asunto(s)
Antibacterianos/análisis , Antibacterianos/farmacología , Compuestos de Azabiciclo/farmacología , Aztreonam/análisis , Aztreonam/farmacología , Bacterias Gramnegativas/efectos de los fármacos , Inhibidores de beta-Lactamasas/farmacología , Cromatografía Liquida , Humanos , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Modelos Teóricos , Espectrometría de Masas en Tándem , Inhibidores de beta-Lactamasas/farmacocinética
9.
Antimicrob Agents Chemother ; 60(1): 368-75, 2016 01.
Artículo en Inglés | MEDLINE | ID: mdl-26525790

RESUMEN

Avibactam is a new non-ß-lactam ß-lactamase inhibitor that shows promising restoration of ceftazidime activity against microorganisms producing Ambler class A extended-spectrum ß-lactamases (ESBLs) and carbapenemases such as KPCs, class C ß-lactamases (AmpC), and some class D enzymes. To determine optimal dosing combinations of ceftazidime-avibactam for treating infections with ceftazidime-resistant Pseudomonas aeruginosa, pharmacodynamic responses were explored in murine neutropenic thigh and lung infection models. Exposure-response relationships for ceftazidime monotherapy were determined first. Subsequently, the efficacy of adding avibactam every 2 h (q2h) or q8h to a fixed q2h dose of ceftazidime was determined in lung infection for two strains. Dosing avibactam q2h was significantly more efficacious, reducing the avibactam daily dose for static effect by factors of 2.7 and 10.1, whereas the mean percentage of the dosing interval that free drug concentrations remain above the threshold concentration of 1 mg/liter (%fT>C(T) 1 mg/liter) yielding bacteriostasis was similar for both regimens, with mean values of 21.6 (q2h) and 18.5 (q8h). Dose fractionation studies of avibactam in both the thigh and lung models indicated that the effect of avibactam correlated well with %fT>C(T) 1 mg/liter. This parameter of avibactam was further explored for four P. aeruginosa strains in the lung model and six in the thigh model. Parameter estimates of %fT>C(T) 1 mg/liter for avibactam ranged from 0 to 21.4% in the lung model and from 14.1 to 62.5% in the thigh model to achieve stasis. In conclusion, addition of avibactam enhanced the effect of ceftazidime, which was more pronounced at frequent dosing and well related with %fT>C(T) 1 mg/liter. The thigh model appeared more stringent, with higher values, ranging up to 62.5% fT>C(T) 1 mg/liter, required for a static effect.


Asunto(s)
Antibacterianos/farmacocinética , Compuestos de Azabiciclo/farmacocinética , Ceftazidima/farmacocinética , Neutropenia/tratamiento farmacológico , Infecciones por Pseudomonas/tratamiento farmacológico , Animales , Animales no Consanguíneos , Antibacterianos/sangre , Antibacterianos/farmacología , Compuestos de Azabiciclo/sangre , Compuestos de Azabiciclo/farmacología , Ceftazidima/sangre , Ceftazidima/farmacología , Recuento de Colonia Microbiana , Esquema de Medicación , Combinación de Medicamentos , Femenino , Pulmón/efectos de los fármacos , Pulmón/microbiología , Pulmón/patología , Ratones , Pruebas de Sensibilidad Microbiana , Neutropenia/sangre , Neutropenia/complicaciones , Neutropenia/microbiología , Especificidad de Órganos , Infecciones por Pseudomonas/sangre , Infecciones por Pseudomonas/complicaciones , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/crecimiento & desarrollo , Muslo/microbiología , Muslo/patología
11.
Sci Rep ; 5: 11827, 2015 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-26168713

RESUMEN

With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance. ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea, operates by a novel mode-of-inhibition against bacterial type II topoisomerases. Incorporating an oxazolidinone on the scaffold mitigated toxicological issues often seen with topoisomerase inhibitors. Organisms resistant to other topoisomerase inhibitors were not cross-resistant with ETX0914 nor were spontaneous resistant mutants to ETX0914 cross-resistant with other topoisomerase inhibitor classes, including the widely used fluoroquinolone class. Preclinical evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissues and efficacy in a murine Staphylococcus aureus infection model that served as a surrogate for predicting efficacious exposures for the treatment of Neisseria gonorrhoeae infections. A wide safety margin to the efficacious exposure in toxicological evaluations supported progression to Phase 1. Dosing ETX0914 in human volunteers showed sufficient exposure and minimal adverse effects to expect a highly efficacious anti-gonorrhea therapy.


Asunto(s)
Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Barbitúricos/farmacología , Barbitúricos/uso terapéutico , Gonorrea/tratamiento farmacológico , Compuestos de Espiro/farmacología , Compuestos de Espiro/uso terapéutico , Inhibidores de Topoisomerasa II/farmacología , Inhibidores de Topoisomerasa II/uso terapéutico , Adulto , Animales , Antibacterianos/química , Barbitúricos/química , ADN-Topoisomerasas de Tipo II/química , Modelos Animales de Enfermedad , Perros , Relación Dosis-Respuesta a Droga , Farmacorresistencia Bacteriana , Femenino , Fluoroquinolonas/farmacología , Gonorrea/microbiología , Haplorrinos , Humanos , Isoxazoles , Masculino , Ratones , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Modelos Moleculares , Conformación Molecular , Morfolinas , Mutación , Neisseria gonorrhoeae/efectos de los fármacos , Neisseria gonorrhoeae/genética , Oxazolidinonas , Ratas , Compuestos de Espiro/química , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/efectos de los fármacos , Inhibidores de Topoisomerasa II/química , Adulto Joven
12.
Nat Chem Biol ; 11(6): 416-23, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25894085

RESUMEN

Many drug candidates fail in clinical trials owing to a lack of efficacy from limited target engagement or an insufficient therapeutic index. Minimizing off-target effects while retaining the desired pharmacodynamic (PD) response can be achieved by reduced exposure for drugs that display kinetic selectivity in which the drug-target complex has a longer half-life than off-target-drug complexes. However, though slow-binding inhibition kinetics are a key feature of many marketed drugs, prospective tools that integrate drug-target residence time into predictions of drug efficacy are lacking, hindering the integration of drug-target kinetics into the drug discovery cascade. Here we describe a mechanistic PD model that includes drug-target kinetic parameters, including the on- and off-rates for the formation and breakdown of the drug-target complex. We demonstrate the utility of this model by using it to predict dose response curves for inhibitors of the LpxC enzyme from Pseudomonas aeruginosa in an animal model of infection.


Asunto(s)
Amidohidrolasas/antagonistas & inhibidores , Antibacterianos/farmacología , Inhibidores Enzimáticos/farmacología , Ácidos Hidroxámicos/farmacología , Treonina/análogos & derivados , Animales , Antibacterianos/química , Antibacterianos/farmacocinética , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacocinética , Ácidos Hidroxámicos/química , Ácidos Hidroxámicos/farmacocinética , Cinética , Ratones Endogámicos , Pruebas de Sensibilidad Microbiana , Modelos Biológicos , Estructura Molecular , Unión Proteica , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/enzimología , Treonina/química , Treonina/farmacocinética , Treonina/farmacología , Factores de Tiempo
13.
AAPS J ; 17(2): 462-73, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25630504

RESUMEN

The application of modeling and simulation techniques is increasingly common in preclinical stages of the drug discovery and development process. A survey focusing on preclinical pharmacokinetic/pharmacodynamics (PK/PD) analysis was conducted across pharmaceutical companies that are members of the International Consortium for Quality and Innovation in Pharmaceutical Development. Based on survey responses, ~68% of companies use preclinical PK/PD analysis in all therapeutic areas indicating its broad application. An important goal of preclinical PK/PD analysis in all pharmaceutical companies is for the selection/optimization of doses and/or dose regimens, including prediction of human efficacious doses. Oncology was the therapeutic area with the most PK/PD analysis support and where it showed the most impact. Consistent use of more complex systems pharmacology models and hybrid physiologically based pharmacokinetic models with PK/PD components was less common compared to traditional PK/PD models. Preclinical PK/PD analysis is increasingly being included in regulatory submissions with ~73% of companies including these data to some degree. Most companies (~86%) have seen impact of preclinical PK/PD analyses in drug development. Finally, ~59% of pharmaceutical companies have plans to expand their PK/PD modeling groups over the next 2 years indicating continued growth. The growth of preclinical PK/PD modeling groups in pharmaceutical industry is necessary to establish required resources and skills to further expand use of preclinical PK/PD modeling in a meaningful and impactful manner.


Asunto(s)
Simulación por Computador , Evaluación Preclínica de Medicamentos/métodos , Industria Farmacéutica/métodos , Modelos Biológicos , Recolección de Datos , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Descubrimiento de Drogas/métodos , Industria Farmacéutica/estadística & datos numéricos , Humanos
14.
J Med Chem ; 57(21): 9078-95, 2014 Nov 13.
Artículo en Inglés | MEDLINE | ID: mdl-25286019

RESUMEN

The compounds described herein with a spirocyclic architecture fused to a benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the inhibition of precursor thymidine into DNA during cell growth. Activity resided in the configurationally lowest energy (2S,4R,4aR) diastereomer. Highly active compounds against Staphylococcus aureus had sufficiently high solubility, high plasma protein free fraction, and favorable pharmacokinetics to suggest that in vivo efficacy could be demonstrated, which was realized with compound (-)-1 in S. aureus mouse infection models. A high drug exposure NOEL on oral dosing in the rat suggested that a high therapeutic margin could be achieved. Importantly, (-)-1 was not cross-resistant with other DNA gyrase inhibitors such as fluoroquinolone and aminocoumarin antibacterials. Hence, this class shows considerable promise for the treatment of infections caused by multidrug resistant bacteria, including S. aureus.


Asunto(s)
Antibacterianos/síntesis química , Barbitúricos/síntesis química , Compuestos Heterocíclicos de 4 o más Anillos/síntesis química , Isoxazoles/síntesis química , Inhibidores de Topoisomerasa II/síntesis química , Animales , Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Barbitúricos/farmacocinética , Barbitúricos/uso terapéutico , Femenino , Fluoroquinolonas/farmacología , Compuestos Heterocíclicos de 4 o más Anillos/farmacocinética , Compuestos Heterocíclicos de 4 o más Anillos/uso terapéutico , Humanos , Concentración 50 Inhibidora , Isoxazoles/farmacocinética , Isoxazoles/uso terapéutico , Masculino , Ratones , Piridonas/síntesis química , Piridonas/farmacocinética , Piridonas/uso terapéutico , Ratas Wistar , Compuestos de Espiro/síntesis química , Compuestos de Espiro/farmacocinética , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Estereoisomerismo , Relación Estructura-Actividad , Inhibidores de Topoisomerasa II/farmacocinética , Inhibidores de Topoisomerasa II/uso terapéutico
15.
Drug Discov Today ; 18(15-16): 764-75, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23726890

RESUMEN

Model-based drug discovery (MBDDx) aims to build and continuously improve the quantitative understanding of the relation between drug exposure (target engagement) efficacy and safety, to support target validation; to define compound property criteria for lead optimization and safety margins; to set the starting dose; and to predict human dose and scheduling for clinical candidates alone, or in combination with other medicines. AstraZeneca has systematically implemented MBDDx within all drug discovery programs, with a focused investment to build a preclinical modeling and simulation capability and an in vivo information platform and architecture, the implementation, impact and learning of which are discussed here.


Asunto(s)
Descubrimiento de Drogas/métodos , Modelos Biológicos , Preparaciones Farmacéuticas/química , Animales , Descubrimiento de Drogas/tendencias , Evaluación Preclínica de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/tendencias , Humanos , Preparaciones Farmacéuticas/metabolismo
16.
Antimicrob Agents Chemother ; 56(12): 6137-46, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22985878

RESUMEN

The combination of ceftazidime and avibactam possesses potent activity against resistant Gram-negative pathogens, including Pseudomonas aeruginosa. We compared the efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam using a hollow-fiber system and neutropenic and immunocompetent murine thigh infection models. Twenty-seven clinical P. aeruginosa isolates with ceftazidime MICs of 8 to 128 mg/liter and ceftazidime-avibactam MICs of 4 to 32 mg/liter were utilized in neutropenic mouse studies; 15 of the isolates were also evaluated in immunocompetent mice. Six isolates were studied in both the hollow-fiber system and the neutropenic mouse. In both systems, the free drug concentration-time profile seen in humans given 2 g of ceftazidime every 8 h (2-h infusion), with or without avibactam at 500 mg every 8 h (2-h infusion), was evaluated. In vivo activity was pharmacodynamically predictable based on the MIC. Ceftazidime decreased bacterial densities by ≥0.5 log unit for 10/27 isolates, while ceftazidime-avibactam did so for 22/27 isolates. In immunocompetent animals, enhancements in activity were seen for both drugs, with ceftazidime achieving reductions of ≥0.3 log unit for 10/15 isolates, whereas ceftazidime-avibactam did so against all 15 isolates. In vitro, ceftazidime resulted in regrowth by 24 h against all isolates, while ceftazidime-avibactam achieved stasis or better against 4/7 isolates. Mutants with elevated ceftazidime-avibactam MICs appeared after 24 h from 3/7 isolates studied in vitro; however, no resistant mutants were detected in vivo. Against this highly ceftazidime-nonsusceptible population of P. aeruginosa, treatment with human simulated doses of ceftazidime-avibactam resulted in pharmacodynamically predictable activity, particularly in vivo, against isolates with MICs of ≤16 mg/liter, and this represents a potential new option to combat these difficult-to-treat pathogens.


Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Compuestos de Azabiciclo/administración & dosificación , Compuestos de Azabiciclo/uso terapéutico , Ceftazidima/administración & dosificación , Ceftazidima/uso terapéutico , Infecciones por Pseudomonas/tratamiento farmacológico , Animales , Farmacorresistencia Bacteriana , Femenino , Humanos , Inmunocompetencia , Ratones , Ratones Endogámicos ICR , Pruebas de Sensibilidad Microbiana , Neutropenia/complicaciones , Pseudomonas aeruginosa/efectos de los fármacos , Muslo/patología , Inhibidores de beta-Lactamasas
17.
J Pharm Biomed Anal ; 36(4): 807-13, 2004 Nov 19.
Artículo en Inglés | MEDLINE | ID: mdl-15533674

RESUMEN

Microdialysis is a technique that allows sampling compounds from the extracellular fluid in different tissues, such as muscle, lung, and brain. However, the feasibility of using this technique with lipopohilic and high molecular weight compounds has been questioned, since these compounds are less likely to diffuse through the dialysis membrane. Therefore, it was the objective of this study to investigate the feasibility of doing microdialysis of docetaxel by determining its recovery by the microdialysis probe. Three different methods were investigated: extraction efficiency, retrodialysis, and no-net-flux. For the first two methods, three different concentrations were tested: 2.5, 5, and 9 mg/l. The recovery obtained for each concentration was 49.3 +/- 6.7 (n = 4), 44.6 +/- 5.4 (n = 3), and 34.7 +/- 2.1 (n = 4) by extraction efficiency, and 53.4 +/- 7.9 (n = 3), 61.4 +/- 7.6 (n = 3), and 64.2 +/- 1.9 (n = 3) by retrodialysis, respectively. The average recovery obtained by no-net-flux was 68.7 +/- 9.6 (n = 5). Although it has been reported that microdialysis cannot be applied to lipophilic compounds, the results here show the opposite. The high recoveries obtained for docetaxel in all methods applied show that the compound can diffuse through the probe membrane. Overall, docetaxel seems to be very suitable for microdialysis despite its lipophilicity and high molecular weight.


Asunto(s)
Microdiálisis/métodos , Taxoides/sangre , Docetaxel , Taxoides/química
18.
RBCF, Rev. bras. ciênc. farm. (Impr.) ; 38(2): 183-190, abr.-jun. 2002. ilus, tab, graf
Artículo en Inglés | LILACS | ID: lil-333582

RESUMEN

The aim of this study was to describe the double peak plasma pharmacokinetic profile of ranitine after oral administration to healthy volunteers using non-compartmental and compartmental analysis. A single 300mg dose of ranitide was given to ten healthy volunteers (5 male and 5 female). Blood samples were drawn at different times and analyzed by HPLC. Plasma profiles were evaluated by non-compartmental and compartmental approaches. The non-compartmental parameters determined were k (0.0054 ñ 0.0010 min-1), t 1/2 (2.2 ñ 0.4 h), Vd steady state/F (265.3 ñ 70.6L), Cl/F (84.8 ñ 24.3 L/h) and AUC (225916 ñ 54099 ng*min/mL)...


Asunto(s)
Humanos , Femenino , Adulto , Ácido Gástrico , Sistema Digestivo , Plasma , Ranitidina , Administración Oral , Recolección de Muestras de Sangre , Cromatografía Líquida de Alta Presión/métodos
19.
RBCF, Rev. bras. ciênc. farm. (Impr.) ; 37(1): 45-49, jan.-abr. 2001. tab
Artículo en Portugués | LILACS | ID: lil-314068

RESUMEN

Cymbopogon citratus (DC) Stapf. é uma gramínea, conhecida popularmente como capim-cidró, capim-cheiroso, erva-cidreira, entre outros, e, em inglês, "lemon grass". A população utiliza o chá ou abafado, preparado a partir de suas folhas, como calmante, digestivo, estomáquico, em dores de cabeça, antiespasmódico, entre outras aplicações. Devido às propriedades antimicrobianas apresentadas pelo óleo volátil de capim-cidró, este trabalho tem por objetivo avaliar a atividade antibacteriana e antifúngica do óleo volátil, extratos aquosos e hidroetanólico, obtidos a partir das folhas frescas e secas da planta. A atividade antimicrobiana foi avaliada pelo método de difusão em ágar, frente aos microrganismos...


Asunto(s)
Bacterias/metabolismo , Candida albicans , Técnicas In Vitro , Aceites Volátiles/análisis , Aceites Volátiles/farmacología , Plantas Medicinales , Bioensayo , Destilación , Inmunodifusión/métodos , Manejo de Especímenes
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...